Who owns Relay Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of RLAY from SEC Form 13F filings across 260 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 260 institutions disclosed 246.8M shares of Relay Therapeutics, Inc. worth $4.58B — about 121.7% of shares outstanding; the largest disclosed holder is SB INVESTMENT ADVISERS (UK) LTD. Source: SEC Form 13F filings, parsed by EvidInvest.
260
13F holders
$4.58B
value, 2026 filers
121.7%
of shares outstanding (246.8M sh)
55
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of RLAY's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | SB INVESTMENT ADVISERS (UK) LTD | 27.9M | $522.1M | 6.8% | 13.8% | 0.0% |
| 2 | FMR LLC | 20.1M | $376.3M | 0.0% | 9.9% | +444.2% |
| 3 | Casdin Capital, LLC | 16.0M | $300.0M | 15.0% | 7.9% | +11.2% |
| 4 | BlackRock, Inc. | 15.3M | $286.0M | 0.0% | 7.5% | +17.8% |
| 5 | PERCEPTIVE ADVISORS LLC | 14.1M | $263.9M | 4.0% | 7% | +44.7% |
| 6 | Commodore Capital LP | 12.0M | $224.5M | 13.4% | 5.9% | -29.4% |
| 7 | STATE STREET CORP | 10.1M | $189.5M | 0.0% | 5% | +62.4% |
| 8 | VANGUARD CAPITAL MANAGEMENT LLC | 9.0M | $167.7M | 0.0% | 4.4% | +21.3% |
| 9 | PRICE T ROWE ASSOCIATES INC /MD/ | 7.7M | $144.2M | 0.0% | 3.8% | +300.5% |
| 10 | Nextech Invest Ltd. | 6.8M | $126.8M | 6.0% | 3.3% | +22.6% |
| 11 | Bellevue Group AG | 6.2M | $115.7M | 2.4% | 3% | -20.6% |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | 4.7M | $88.4M | 0.0% | 2.3% | +34.6% |
| 13 | TCG Crossover Management, LLC | 4.3M | $80.0M | 1.9% | 2.1% | 0.0% |
| 14 | ALLIANCEBERNSTEIN L.P. | 4.1M | $40.8M | 0.0% | 2% | +2719.7% |
| 15 | MORGAN STANLEY | 3.9M | $72.1M | 0.0% | 1.9% | +168.9% |
| 16 | Siren, L.L.C.NEW | 3.6M | $68.3M | 1.4% | 1.8% | new |
| 17 | GOLDMAN SACHS GROUP INC | 3.4M | $63.8M | 0.0% | 1.7% | +34.1% |
| 18 | WESTFIELD CAPITAL MANAGEMENT CO LPNEW | 3.3M | $62.6M | 0.2% | 1.6% | new |
| 19 | Kynam Capital Management, LP | 3.3M | $61.7M | 3.4% | 1.6% | +131.7% |
| 20 | DIMENSIONAL FUND ADVISORS LP | 3.1M | $58.5M | 0.0% | 1.5% | +6.4% |
| 21 | Spruce Street Capital LP | 3.0M | $55.8M | 11.0% | 1.5% | 0.0% |
| 22 | VANGUARD PORTFOLIO MANAGEMENT LLC | 2.9M | $54.1M | 0.0% | 1.4% | +55.2% |
| 23 | BAKER BROS. ADVISORS LP | 2.8M | $52.9M | 0.3% | 1.4% | +143.7% |
| 24 | BANK OF AMERICA CORP /DE/ | 2.7M | $50.4M | 0.0% | 1.3% | +39.1% |
| 25 | MPM BIOIMPACT LLC | 2.4M | $45.2M | 2.8% | 1.2% | +2.4% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.